Fosamax for Male Osteoporosis: Evidence, Risks, and How It Compares to FDA-Approved Options

What Is Alendronate and Why Is It Used Off-Label in Men?

Alendronate belongs to the bisphosphonate drug class. It binds hydroxyapatite on bone surfaces, inhibits osteoclast-mediated resorption, and shifts bone turnover toward net formation. The FDA approved the 70 mg weekly oral tablet for postmenopausal osteoporosis and glucocorticoid-induced osteoporosis in both sexes, but not for idiopathic or hypogonadal male osteoporosis as a primary labeled indication.

Off-label prescribing of alendronate for men is common precisely because osteoporosis is underdiagnosed in the male population. The NOF (National Osteoporosis Foundation) estimates that one in five American men over age 50 will experience an osteoporosis-related fracture in his remaining lifetime, yet men receive bisphosphonate therapy at roughly one-third the rate of women with equivalent T-scores.

Why Men Are Undertreated

Several factors converge. DXA screening guidelines historically focused on women. The primary Medicare coverage criteria for men required a prior fracture or specific disease state until recently. Male osteoporosis is often secondary to low testosterone, glucocorticoid exposure, alcohol use, or prostate cancer androgen-deprivation therapy, so the underlying cause sometimes overshadows anti-resorptive treatment decisions.

The FDA-Approval Gap

Risedronate 35 mg weekly and zoledronic acid 5 mg IV annually carry actual FDA approval for osteoporosis in men, giving clinicians two on-label bisphosphonate options. Alendronate does not share that specific indication. However, the Endocrine Society's 2012 clinical practice guideline on osteoporosis in men explicitly states: "We recommend treatment of men with osteoporosis with bisphosphonates (alendronate, risedronate, or zoledronic acid) to reduce fracture risk," treating alendronate as a first-line option without distinction from the on-label agents for clinical decision-making purposes [1].

The Core Clinical Trial: Orwoll et al. 2000

The most cited evidence supporting alendronate in men comes from the key two-year, double-blind, placebo-controlled RCT published in the New England Journal of Medicine by Orwoll and colleagues (N=241 men aged 31-87 with low bone density or prior vertebral fracture) [2].

Primary Efficacy Results

Men randomized to alendronate 10 mg daily (the dose standard before once-weekly formulations) showed:

• Lumbar spine BMD increased 7.1% vs. 1.8% placebo (P<0.001)
• Femoral neck BMD increased 2.5% vs. 0.1% placebo (P<0.001)
• Total hip BMD increased 2.0% vs. 0.6% placebo

Fracture Outcomes

Vertebral fracture incidence was lower in the alendronate group: 0.8% vs. 7.1% in placebo (relative risk reduction approximately 50%), though the trial was not powered to demonstrate fracture efficacy as a primary endpoint. This means the fracture data should be interpreted cautiously. The Orwoll trial enrolled men regardless of etiology, so the results span both idiopathic and secondary male osteoporosis.

Where the Evidence Gets Thinner

No alendronate trial in men has used non-vertebral fracture reduction as a prospectively powered primary endpoint. That absence is why the GRADE rating for fracture efficacy sits at Low-to-Moderate in men specifically, compared to the High-quality evidence for hip fracture reduction in postmenopausal women from the FIT trial (N=2,027) [3].

Dosing Alendronate Off-Label in Men

When a clinician prescribes alendronate off-label for a male patient, the standard regimen mirrors the postmenopausal dose:

• 70 mg oral tablet once weekly, taken first thing in the morning with 6-8 oz of plain water, at least 30 minutes before food, beverage, or other medication
• 10 mg daily was the original studied dose; once-weekly 70 mg achieves equivalent bioavailability and is preferred for adherence
• Patients must remain fully upright (sitting or standing) for at least 30 minutes after swallowing

Vitamin D (800-1,000 IU/day minimum) and calcium supplementation (total dietary plus supplemental intake reaching 1,000-1,200 mg/day) are co-required. The Endocrine Society guideline specifies that correcting vitamin D deficiency before initiating any bisphosphonate improves response and reduces hypocalcemia risk [1].

Renal Dosing Considerations

Alendronate is contraindicated when creatinine clearance falls below 35 mL/min. Men with CKD stages 3b-5 should not receive it. Zoledronic acid carries similar renal contraindications; for severe CKD, denosumab (Prolia) or teriparatide are generally preferred per the AACE/ACE 2020 guidelines [4].

Risks and Adverse Effects

Upper Gastrointestinal Adverse Effects

The most frequent adverse effects are esophageal and gastric. Alendronate can cause esophagitis, esophageal erosions, and ulceration, particularly if patients do not follow the upright-positioning and fasting requirements. The original RCT in men reported GI adverse events in 27% of alendronate recipients vs. 18% of placebo, though serious upper GI events were uncommon [2].

Absolute contraindications include:

• Esophageal stricture, achalasia, or other esophageal motility disorders
• Inability to sit or stand upright for 30 minutes
• Hypocalcemia (must be corrected first)

Osteonecrosis of the Jaw

Osteonecrosis of the jaw (ONJ) is rare with oral bisphosphonates at osteoporosis doses. A systematic review in the Journal of Bone and Mineral Research estimated the incidence at 1 in 10,000 to 1 in 100,000 patient-years for oral bisphosphonate users at osteoporosis doses, rising sharply with IV bisphosphonates used in oncology [5]. Patients should complete needed dental work before starting, and invasive dental procedures during therapy require coordinated planning with the prescriber.

Atypical Femoral Fracture

Atypical femoral fractures (AFF) are a paradoxical risk of long-term bisphosphonate use, appearing after three or more years of continuous therapy. The FDA added a black box warning in 2010 addressing this risk [6]. The absolute risk remains low: a Swedish cohort study estimated approximately 5 extra AFFs per 10,000 patient-years at five years of use, rising to about 11 per 10,000 patient-years beyond eight years. For most patients, this low absolute risk is outweighed by hip fracture prevention benefits, but the balance shifts in men with lower baseline fracture risk.

Musculoskeletal Pain

Severe bone, joint, or muscle pain after starting a bisphosphonate occurs in a minority of patients. The FDA's safety communication from 2008 described cases of debilitating pain resolving after discontinuation [7]. Most cases begin within days to months of the first dose.

Hypocalcemia

Mild transient drops in serum calcium can occur, especially in men with baseline vitamin D deficiency. Checking 25-hydroxyvitamin D and correcting levels to at least 30 ng/mL before initiation reduces this risk.

How Alendronate Compares to On-Label Options for Men

The table below summarizes the three bisphosphonates relevant to male osteoporosis, highlighting the FDA-approval distinction.

| Agent | FDA-Approved for Men | Typical Dose | Route | Key Male Trial | |---|---|---|---|---| | Alendronate (Fosamax) | No (off-label) | 70 mg weekly | Oral | Orwoll 2000 (N=241) | | Risedronate (Actonel) | Yes | 35 mg weekly | Oral | McClung 2012 | | Zoledronic acid (Reclast) | Yes | 5 mg annually | IV infusion | Boonen 2011 (N=1,199) |

Risedronate as the Closest On-Label Oral Comparator

Risedronate 35 mg weekly carries FDA approval for male osteoporosis. The supporting trial by McClung and colleagues showed lumbar spine BMD gains of 4.5% vs. 0.5% placebo over two years in men (N=284). The absolute BMD gain was somewhat smaller than Orwoll's alendronate data, though direct head-to-head trials in men do not exist. Physicians who want an on-label oral bisphosphonate have a clear alternative.

Zoledronic Acid for Men Who Cannot Take Oral Medications

The HORIZON trial extension (Boonen et al., N=1,199 men) demonstrated that annual IV zoledronic acid 5 mg increased lumbar spine BMD by 6.1% and reduced morphometric vertebral fractures by 67% vs. Placebo over two years [8]. Its once-yearly IV administration is particularly useful for men with GI intolerance to oral bisphosphonates or with poor adherence history.

When Alendronate Still Gets Prescribed Off-Label

Cost drives many decisions. Generic alendronate 70 mg tablets are available for under $10 per month at most US pharmacies, making it far less expensive than brand risedronate or IV zoledronic acid for uninsured or underinsured patients. A thoughtful clinician might prescribe alendronate over risedronate specifically because the per-dose cost difference represents a genuine adherence advantage for some patients.

Special Populations Within Male Osteoporosis

Men on Androgen Deprivation Therapy

Prostate cancer treated with androgen deprivation therapy (ADT) causes rapid, predictable bone loss, often exceeding 5% of lumbar spine BMD per year in the first 12 months. A randomized trial by Greenspan et al. (N=112) showed alendronate 70 mg weekly prevented BMD loss at the spine and hip in men on ADT, with lumbar spine BMD increasing 3.7% vs. A 1.8% loss in the placebo group at one year (P<0.001) [9]. This is one of the better-supported off-label male applications.

Glucocorticoid-Induced Osteoporosis in Men

Alendronate does carry FDA approval for glucocorticoid-induced osteoporosis in men taking prednisone-equivalent doses of at least 7.5 mg/day. This is technically an on-label application. Men starting long-term glucocorticoid therapy should receive baseline DXA and anti-resorptive treatment per the ACR 2022 guidelines if medium-to-high fracture risk is present [10].

Hypogonadal Men

Low testosterone accelerates bone resorption. Testosterone replacement therapy alone improves BMD modestly, but the combination of testosterone and a bisphosphonate provides additive benefit in hypogonadal osteoporosis. A 2008 trial by Amory et al. Showed the combination increased lumbar spine BMD by 9.2% over two years, compared with 5.3% for testosterone alone and 7.0% for alendronate alone.

Monitoring and Drug Holidays

Baseline and Follow-Up DXA

DXA at lumbar spine, total hip, and femoral neck should be performed at baseline and repeated at 12-24 months to assess response. A T-score improvement of 0.03 to 0.06 per year at the hip is considered a minimally meaningful response. Lack of response warrants re-evaluation of adherence, calcium/vitamin D intake, and secondary causes.

Bone Turnover Markers

Serum C-terminal telopeptide (CTX) or urine N-terminal telopeptide (NTX) fall significantly within 3-6 months of starting alendronate. A CTX drop of at least 25-30% from baseline suggests adequate adherence and pharmacological response. This monitoring approach is cost-effective and does not require waiting two years for a repeat DXA.

Drug Holidays

After three to five years of alendronate in men at moderate fracture risk, a drug holiday of one to two years may be appropriate. Alendronate persists in bone mineral for years after discontinuation due to its high affinity for hydroxyapatite, so some anti-fracture benefit continues during holidays. The American Society for Bone and Mineral Research task force suggests re-evaluating patients on drug holidays annually with fracture risk assessment, resuming therapy if T-score drops below -2.5 or a fracture occurs [11].

Guideline Positions on Alendronate in Men

Three major societies address this directly:

The Endocrine Society 2012 guideline states: "We recommend treatment of men 50 years of age and older who have a hip or vertebral fracture or who have a T-score of -2.5 or below with pharmacological therapy" and names alendronate among the first-line agents [1].

The AACE/ACE 2020 postmenopausal osteoporosis guidelines (which contain recommendations applicable to male osteoporosis by reference) grade oral bisphosphonates as Grade A evidence for fracture prevention, with the caveat that male-specific trial data are less extensive than postmenopausal data [4].

The American College of Rheumatology 2022 guideline for glucocorticoid-induced osteoporosis explicitly approves alendronate as an on-label option for men taking chronic glucocorticoids, providing one firm regulatory footing within a subset of male patients [10].

Shared Decision-Making: The Practical Conversation

When a physician considers alendronate off-label for a male patient, the conversation typically weighs five variables:

1. Baseline T-score and FRAX 10-year fracture probability
2. Whether an on-label alternative (risedronate, zoledronic acid) is accessible and affordable
3. GI history and ability to comply with dosing instructions
4. Duration of planned therapy and AFF risk at that duration
5. Secondary causes of bone loss that may need separate treatment

A FRAX 10-year major osteoporotic fracture probability above 20%, or hip fracture probability above 3%, generally triggers a treatment threshold recommendation per the NOF guidelines, applicable to men and women equally. At that threshold, the cost and off-label status of alendronate become secondary to initiating effective therapy promptly.

Generic alendronate 70 mg costs roughly $8-$12 per month compared to approximately $55-$80 per month for generic risedronate 35 mg as of 2024 at major US pharmacy chains, and IV zoledronic acid administration adds infusion center fees. For a patient whose out-of-pocket exposure drives adherence, the off-label status of alendronate matters less than the likelihood that the prescription will actually be filled.